FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washing

ton, D.C. 20549	OMB APPROVAL

OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

1. Name and Address of Reporting Person* Dolecek Gayle R						2. Issuer Name and Ticker or Trading Symbol Sucampo Pharmaceuticals, Inc. [SCMP]										Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) 4520 EA	Last) (First) (Middle) 4520 EAST WEST HWY, 3RD FLOOR							3. Date of Earliest Transaction (Month/Day/Year) 03/18/2014											Other (s		
(Street) BETHESDA MD 20814					_	4. If Amendment, Date of Original Filed (Month/Day/Year)										e) X Form Form					
(City)	(S		(Zip)	n Dori	untive		ourit	ioo A		rad F	Nio.	20004	of or	Bon	oficial	ly Owns					
1. Title of Security (Instr. 3) 2. Trans Date (Month/				saction	ar) i	2A. Deemed Execution Date, f any (Month/Day/Year)			ransact Code (In	tion	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			d (A) or	5. Amo Securit Benefic Owned	unt of es ially Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
							Code	v	Amount	(A) or (D)		Price	Transa	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)				
Class A Common Stock 03/18/							2014			M		1,200	O A \$		\$4.4	1 1	1,200		D		
Class A (Common St	ock		03/1	8/2014	4				S ⁽¹⁾		1,200)	D	\$8.03	(2)	0	D			
		٦	able II -									sed of onverti				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Executior if any (Month/Da	Date,	4. Transaction Code (Instr. 8)		of Deri Sec Acq (A) Disp of (I	oosed D) tr. 3, 4	Expi	ate Exer iration E nth/Day/	Date		e and 7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	s Blly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)	
					Code	v	(A)	(D)	Date Exer	e rcisable		piration ate	Title	0 N 0	Amount or Number of Shares						
Employee Stock Option (Right to Buy)	\$4.41	03/18/2014			M			1,200	05/0	02/2013	05	5/02/2021	Class Comn Stoc	non	1,200	\$0	313,36	57	D		

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on June 13, 2013.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$8.00 to \$8.07, inclusive. The reporting person undertakes to provide Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

03/21/2014 /s/ Gayle R. Dolecek

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.